Management of Neuroendocrine Tumors: Current and Future Therapies

Kjell E Öberg


Expert Rev Endocrinol Metab. 2011;6(1):49-62. 

In This Article

Five-year View

New biomarkers for early diagnosis and recurrence of disease will be developed. Molecular imaging will increase in the management of NETs. 68Ga-DOTA octreotate will probably be preferred to Octreoscan in the near future. The novel multireceptor ligand analogue pasireotide has demonstrated efficacy in patients with NETs, including those with metastatic NETs refractory or resistant to, or inadequately controlled with, current somatostatin analogues;[53,91] pasireotide has also shown evidence of antiproliferative effects in vitro.[92,93] A randomized, double-blind Phase III study comparing pasireotide LAR with octreotide LAR in patients with metastatic NETs whose symptoms of carcinoid syndrome were inadequately controlled with their current somatostatin analogue therapy is currently ongoing. It seems likely that somatostatin analogues will be used more frequently in combination with other medical therapies such as mTOR as well as tyrosine kinase inhibitors; positive antiproliferative effects have been seen in patients administered both octreotide LAR and everolimus. Combination trials of everolimus with PRRT will start in Europe as well as everolimus in combination with temozolomide. Sunitinib alone or in combination with somatostatin analogs as well as mTOR inhibitors or VEGF inhibitors (bevacizumab) will be tested. The precise role of everolimus or sunitinib in the treatment algorithm of pancreatic NETs has to be established in forthcoming studies.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.